Journal
ANNALS OF ONCOLOGY
Volume 25, Issue 7, Pages 1260-1270Publisher
ELSEVIER
DOI: 10.1093/annonc/mdu013
Keywords
cancer; pancreatic ductal adenocarcinoma; advanced disease; treatment; targeted therapies
Categories
Funding
- Baden-Wurttemberg Stiftung by the Eliteprogramme for Postdocs
- Else-Kroner-Fresenius-Stiftung [2011_A200]
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death in the Western world. Owing to a lack of specific symptoms and no accessible precursor lesions, primary diagnosis is commonly delayed, resulting in only 15%-20% of patients with potentially curable disease. The standard of care in advanced pancreatic cancer has improved. Apart from gemcitabine (plus erlotinib), FOLFIRINOX and the combination of gemcitabine plus nab-paclitaxel are novel and promising therapeutic options for patients with metastatic PDAC. A better molecular understanding of pancreatic cancer has led to the identification of a variety of potential molecular therapeutic targets. Many targeted therapies are currently under clinical evaluation in combination with standard therapies for PDAC. This review highlights the current status of targeted therapies and their potential benefit for the treatment of advanced PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available